Inquiry Basket
CAS No.:
Cat No.: BADC-00734
4.5 
MC-vc-PAB-DMEA-(PEG2)-duocarmycin SA is a drug-linker conjugate for ADC by using Duocarmycin SA (a potent antitumor antibiotic), linked via MC-vc-PAB-DMEA-(PEG2).
Structure of
* For research and manufacturing use only. We do not sell to patients.
| Size | Price | Stock | Quantity |
|---|---|---|---|
| -- | $-- | In stock |
Looking for different specifications? Click to request a custom quote!
Capabilities & Facilities
Popular Publications Citing BOC Sciences Products
MC-vc-PAB-DMEA-(PEG2)-duocarmycin SA is a powerful drug-linker conjugate designed for use in antibody-drug conjugates (ADCs), combining the potent antitumor activity of Duocarmycin SA with a specialized linker system. The linker, consisting of MC-vc-PAB-DMEA-(PEG2), plays a crucial role in ensuring that the cytotoxic agent is released selectively at the target site, minimizing systemic toxicity. This precision targeting is essential for enhancing the therapeutic index of the drug and optimizing the efficacy of cancer treatments. By utilizing ADCs, MC-vc-PAB-DMEA-(PEG2)-duocarmycin SA offers a more effective and less toxic alternative to traditional chemotherapy.
The linker structure in MC-vc-PAB-DMEA-(PEG2)-duocarmycin SA, particularly the PEG2 (polyethylene glycol) component, provides enhanced solubility and stability, enabling the conjugate to remain intact during circulation in the bloodstream. PEGylation improves the pharmacokinetics of the conjugate, prolonging its half-life and reducing renal clearance. This ensures that the conjugate can remain in the bloodstream longer and reach the target tumor cells effectively. The cleavable nature of the MC-vc-PAB-DMEA linker also ensures that the Duocarmycin SA is only released once the ADC reaches its target, thereby reducing off-target effects and improving the therapeutic outcome.
The use of Duocarmycin SA as the cytotoxic payload is another critical aspect of the MC-vc-PAB-DMEA-(PEG2)-duocarmycin SA conjugate. Duocarmycin is known for its potent antitumor activity, specifically its ability to form covalent bonds with DNA, leading to cell cycle arrest and apoptosis. Its high cytotoxicity is harnessed through the ADC platform, allowing for localized and controlled delivery to cancer cells, which are overexpressed with the specific antibody. This selectivity significantly enhances the precision of treatment, allowing for higher doses of the cytotoxic agent to be delivered directly to the tumor without affecting healthy cells.
MC-vc-PAB-DMEA-(PEG2)-duocarmycin SA is particularly promising in the treatment of cancers that are difficult to target with traditional chemotherapies. Its ADC design allows for the delivery of Duocarmycin SA to tumors that express specific antigens, offering a personalized therapeutic approach. Additionally, its ability to target resistant cancer cells that have developed resistance to other treatments further underscores its potential in overcoming the limitations of conventional chemotherapy. This makes it an important tool in the development of next-generation cancer therapies.
| Catalog | Product Name | CAS | Inquiry |
|---|---|---|---|
| BADC-00811 | Duocarmycin DM free base | 1116745-06-2 | |
| BADC-00337 | Seco-Duocarmycin TM | 1142188-60-0 | |
| BADC-00223 | Duocarmycin A | 118292-34-5 | |
| BADC-00362 | Duocarmycin B1 | 124325-93-5 | |
| BADC-00341 | Seco-Duocarmycin SA | 152785-82-5 | |
| BADC-00605 | Duocarmycin TM | 157922-77-5 | |
| BADC-00332 | Seco-DuocarmycinCN | 1613286-54-6 | |
| BADC-00333 | Seco-DuocarmycinDMG | 1613286-55-7 | |
| BADC-00342 | Seco-Duocarmycin MA | 1613286-57-9 | |
| BADC-00609 | Duocarmycin MB | 1613286-58-0 |
What is MC-vc-PAB-DMEA-(PEG2)-duocarmycin SA?
MC-vc-PAB-DMEA-(PEG2)-duocarmycin SA is a duocarmycin-based cytotoxic agent designed for ADC applications, featuring a maleimide coupling site (MC), a valine-citrulline cleavable linker, a PAB self-immolative spacer, and a PEG2-DMEA solubilizer for improved pharmacological properties.
21/7/2022
We are interested in how maleimide conjugation works with MC-vc-PAB-DMEA-(PEG2)-duocarmycin SA.
The maleimide group reacts with thiol groups on cysteine residues of antibodies, forming stable thioether bonds. This allows precise conjugation, maintaining payload stability during circulation until enzymatic cleavage occurs inside target cells.
19/10/2017
Could you explain the role of the PEG2-DMEA segment in MC-vc-PAB-DMEA-(PEG2)-duocarmycin SA?
PEG2-DMEA improves water solubility and reduces hydrophobic interactions, enhancing ADC formulation stability and reducing aggregation, which facilitates higher drug-to-antibody ratios and better in vivo tolerability.
12/1/2021
Good afternoon! Could you kindly explain how the payload is released inside target cells?
The valine-citrulline linker is cleaved by lysosomal proteases, triggering self-immolation of the PAB spacer and releasing the duocarmycin payload, which binds DNA and induces cytotoxicity specifically in the target cells.
24/7/2018
Good morning! For what research applications is MC-vc-PAB-DMEA-(PEG2)-duocarmycin SA used?
This payload is used in ADC design and optimization studies, including linker evaluation, cytotoxicity assays, pharmacokinetics, and targeted delivery studies in preclinical oncology models.
24/2/2016
— Dr. Sofia Weber, ADC Research Scientist (Germany)
MC-vc-PAB-DMEA-(PEG2)-duocarmycin SA showed excellent stability and reactivity in our ADC projects.
12/1/2021
— Mr. James Brown, Senior Chemist (UK)
This linker allowed efficient payload attachment with minimal side reactions, streamlining our workflow.
24/2/2016
— Dr. Emilia Rossi, Medicinal Chemist (Italy)
MC-vc-PAB-DMEA-(PEG2)-duocarmycin SA consistently produced high-quality ADCs with predictable DAR.
24/7/2018
— Prof. Martin Klein, Biochemistry Professor (Netherlands)
We were impressed by the solubility and handling of MC-vc-PAB-DMEA-(PEG2)-duocarmycin SA.
21/7/2022
— Dr. Helena Fischer, Senior Scientist (Germany)
Excellent batch uniformity and performance, enabling efficient preclinical ADC testing.
— Mr. Victor Adams, Bioconjugation Specialist (USA)
MC-vc-PAB-DMEA-(PEG2)-duocarmycin SA integrated seamlessly into our ADC development workflow.
19/10/2017
MC-vc-PAB-DMEA-(PEG2)-duocarmycin SA
Required fields are marked with *
MC-vc-PAB-DMEA-(PEG2)-duocarmycin SA
Required fields are marked with *
Contact our experts today for pricing and comprehensive details on our ADC offerings.
From cytotoxin synthesis to linker design, discover our specialized services that complement your ADC projects.
Learn more about payload design, linker strategies, and integrated CDMO support through our curated ADC content.
Find exactly what your project needs from our expanded range of ADCs, offering flexible options to fit your timelines and goals.
